EXEL vs LLY · P/E 17, rev $628.7M vs P/E 39, rev $22.97B
Exelixis Inc (EXEL) versus Eli Lilly and Company (LLY) — a side-by-side from cached financials, not a winner call.
Exelixis Inc (EXEL) is a biotechnology company listed on US.
Eli Lilly and Company (LLY) is a drug manufacturers - general company listed on NYSE. It is led by David Ricks.
Latest reported EXEL revenue for 2026-07-03 was $628.7M. Net income was $212.1M. Revenue was up 2.9% from 2026-04-03 to 2026-07-03. EXEL currently screens at market cap $12.69B and trailing P/E 16.7.
Latest reported LLY revenue for 2026-06-30 was $22.97B. Net income was $7.09B. Revenue was up 16.0% from 2026-03-31 to 2026-06-30. LLY currently screens at market cap $991.62B and trailing P/E 39.5.
EXEL currently screens at market cap $12.69B and trailing P/E 16.7. LLY currently screens at market cap $991.62B and trailing P/E 39.5.
Not investment advice. Open the EXEL and LLY stock pages for the full models.
Not investment advice.